National Bank of Canada FI Raises Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

National Bank of Canada FI raised its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 5,472.4% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,019,526 shares of the company's stock after purchasing an additional 1,001,230 shares during the period. National Bank of Canada FI owned about 0.09% of Teva Pharmaceutical Industries worth $22,470,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Wilmington Savings Fund Society FSB purchased a new stake in Teva Pharmaceutical Industries during the third quarter worth $50,000. Ameliora Wealth Management Ltd. bought a new stake in Teva Pharmaceutical Industries during the fourth quarter valued at about $66,000. IFP Advisors Inc grew its stake in Teva Pharmaceutical Industries by 96.1% in the fourth quarter. IFP Advisors Inc now owns 3,999 shares of the company's stock valued at $88,000 after purchasing an additional 1,960 shares during the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors acquired a new stake in Teva Pharmaceutical Industries in the 4th quarter worth approximately $104,000. Finally, Assetmark Inc. grew its position in Teva Pharmaceutical Industries by 1,370.3% during the 4th quarter. Assetmark Inc. now owns 5,205 shares of the company's stock worth $115,000 after purchasing an additional 4,851 shares during the last quarter. Institutional investors own 54.05% of the company's stock.

Teva Pharmaceutical Industries Stock Up 0.0 %

NYSE:TEVA traded up $0.01 during midday trading on Tuesday, reaching $13.95. The company had a trading volume of 4,622,397 shares, compared to its average volume of 9,756,410. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97. The firm has a market capitalization of $15.81 billion, a price-to-earnings ratio of -9.61, a PEG ratio of 1.44 and a beta of 0.72. The stock's fifty day simple moving average is $16.36 and its 200-day simple moving average is $17.99. Teva Pharmaceutical Industries Limited has a 12-month low of $12.51 and a 12-month high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. On average, sell-side analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

Analyst Ratings Changes

TEVA has been the subject of several research reports. Piper Sandler lifted their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a research note on Friday, January 17th. UBS Group decreased their target price on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a report on Thursday, January 30th. Bank of America cut their price target on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating on the stock in a research report on Thursday, March 6th. Barclays cut their price target on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a research note on Thursday, January 30th. Finally, StockNews.com upgraded Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research report on Friday. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat.com, Teva Pharmaceutical Industries has an average rating of "Moderate Buy" and a consensus price target of $23.43.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.